
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's financial outlook is bolstered by projected product sales increasing from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting robust revenue growth potential. The recent $1.5 billion debt deal, secured at a competitive interest rate, enhances the company's financial flexibility, positioning it well to navigate uncertainties and capitalize on future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to restore gross margins, which had compressed from 85% during the pandemic to 30% in 2023, back to 50% by 2025, signaling a positive trend in operational profitability.
Bears say
Moderna has reported a significant decline in COVID vaccine sales, with 2023 revenues at $6.7 billion compared to $18 billion in 2022, prompting a reduction in revenue guidance for 2025 due to waning vaccination rates. Additionally, the firm faces competitive pressures in the respiratory vaccine segment, particularly from approved vaccines for RSV, and slower pipeline advancements beyond respiratory applications. Overall, the projected long-term revenue potential for COVID-related products has been substantially lowered, compounding the firm's challenges in achieving robust growth in the near future.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares